Clinical Trial

Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Delayed/slow graft function is the most common complication after kidney transplantation with an incidence over 20% and is the result of ischemia-reperfusion injury. The increased use of marginal kidney grafts to palliate the organ shortage is leading to a continued rise in the incidence of delayed/slow graft function. Delayed/slow graft function, however, is associated with an increased risk of acute rejection and graft failure. There are currently no clinically accepted biomarkers and no specific treatments for delayed/slow graft function. Regulatory T cells are protective in ischemia-reperfusion injury and rejection by suppressing pathologic immune responses. We hypothesize that the pre-transplant measurement of highly suppressive regulatory T cell is an accurate biomarker for delayed/slow graft function and its immunologic consequences. Ultimately, marginal kidney graft allocation could be directed to regulatory T cell-robust recipients and regulatory T cell-directed therapies could decrease marginal kidney graft discards without increasing delayed/slow graft function or impacting outcomes.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2020-06-01; most recent amendment 2025-12-09.
Status change: Recruiting → Active, Not Recruiting 2023-11-08
Trial Details
NCT Number NCT04414111
Lead Sponsor St. Louis University
Collaborators: Mid-America Transplant
Conditions DGF, Kidney Transplant; Complications
Enrollment 180 participants
Start Date 2020-12-07
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-17